Real-World data on vericiguat for heart failure in india

NCT ID NCT06632483

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at medical records from over 600 Indian adults with chronic heart failure who were prescribed vericiguat between 2022 and 2023. Researchers want to see how the drug is used in routine care, how well it works, and what side effects occur. No new tests or visits are needed—only existing data is reviewed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congestive heart failure heart failure symptomatic heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Many locations

    Multiple Locations, India